Another step forward in the progressive rebuilding
30/10/24 -"Clariane’s turnover growth continued to be driven by increases in both volume and pricing across all the business segments and regions. The group also advanced its €1bn disposal program for ..."
Pages
51
Language
English
Published on
30/10/24
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...